NASDAQ: MGXMetagenomi Inc Stock
$7.53+0.79 (+11.72%)
Updated Apr 26, 2024
MGX Price
$7.53
Fair Value Price
N/A
Market Cap
$282.17M
52 Week Low
$6.50
52 Week High
$12.74
P/E
-0.38x
P/B
-2.08x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$44.76M
Earnings
-$68.26M
Gross Margin
100%
Operating Margin
-134.57%
Profit Margin
-152.5%
Debt to Equity
-1.1
Operating Cash Flow
-$91M
Beta
2.57
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MGX Overview
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MGX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MGX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MGX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
MGX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more MGX due diligence checks available for Premium users.
Be the first to know about important MGX news, forecast changes, insider trades & much more!
MGX News
Valuation
MGX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.38x
Industry
14.88x
Market
41.14x
MGX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.08x
Industry
5.85x
MGX's financial health
Profit margin
Revenue
$12.4M
Net Income
-$19.3M
Profit Margin
-155.6%
MGX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MGX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$364.8M
Liabilities
$149.7M
Debt to equity
-1.1
MGX's short-term assets ($278.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MGX's short-term assets ($278.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MGX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MGX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.6M
Investing
$60.6M
Financing
-$1.3M
MGX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MGX vs Biotech Stocks
Metagenomi Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.